The clinical response to natalizumab in patients with multiple sclerosis (MS) may be significantly influenced by genetic variation. Mutations in genes related to the drug’s mechanism of action or the pathological milieu of MS can contribute substantially to interindividual differences in treatment outcomes. This review aims to provide an overview of previous studies that have examined genetic polymorphisms associated with the clinical efficacy of natalizumab. A systematic literature search was conducted across the PubMed, Google Scholar, and ResearchGate databases using targeted keywords relevant to the subject matter. Several genetic loci were found to be linked to natalizumab responsiveness, including the integrin subunit alpha 4 (ITGA4), the nicotinamide adenine dinucleotide phosphate (NADPH) quinone oxidoreductase 1 (NQO1), the glutathione S-transferase pi 1 (GSTP1), the glycoprotein VI platelet (GP6), and the alpha serine/threonine-protein kinase (AKT1) genes. Further research is warranted in order to explore the influence of genetic factors on treatment response across diverse populations. By synthesizing existing evidence, this review underscores the role of pharmacogenomics in optimizing the use of natalizumab and highlights its efficacy and safety in improving clinical outcomes.
Genetic polymorphisms and adverse effects that affect the natalizumab clinical response: a review
natalizumab
genetic polymorphisms
multiple sclerosis
mutations
response
Publication Date
Mon Jun 01 2026
Journal Name
International Journal Of Robotics And Control Systems
Integrating Multimodal Emotion Recognition with Deep Q-Learning for Adaptive Social Robot Interaction
Adaptive Response Generation
Deep Q-Learning
Emotionally Intelligent Social Robots
Human–Robot Interaction in Healthcare
Multimodal Emotion Recognition
Multimodal Fusion Architecture
